The company stops dosing in the troubled Tamarack trial, and is going quiet until ESMO.

But the company hasn’t given details, and used a historical control rather than the study’s own control arm.

Meanwhile, the RayzeBio-originated RYZ101 is back in Action.

Now in Bristol’s hands, BMS-986442 is set to deliver its first clinical data.

But Imfinzi's precise setting is uncertain, and big problems loom for companies pursuing similar trials.

Roche curbs its TIGIT push, while a co-stimulation crunch could be bad news for Regeneron.

An adcom on Imfinzi’s Aegean trial will show whether neoadjuvant and adjuvant benefits must be split out.

Soon after filing to float in Hong Kong, Baili takes HER2 and DLL3-targeting ADCs into the clinic.

ASP3082 grabs some early attention among degraders set to feature at ESMO.

The companies’ PD-(L)1 x VEGF bispecifics will clash in triple-negative breast cancer.